Envisagenics key facts
- Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics.
- Envisagenics’s last known valuation is $150.0M.
- It has raised $40.5M across 2 recorded rounds; the latest was Early Stage VC ($19.2M) in Sep 2021.
- Notable investors include SV Angel, National Institutes of Health, M12, Madrona Venture Group, Hawktail — 24 tracked in total.
- Envisagenics has filed 3 Form Ds with the SEC since 2017, most recently Oct 2021 ($19.2M sold to 24 investors).
- Status: Privately Held (backing).
Who backs Envisagenics
24+- ·The complete investor list: 24 names
- ·Watch Envisagenics: the Monday email on marks, rounds and moves
Envisagenics funding rounds
2 roundsEnvisagenics valuation
Envisagenics's last known valuation is $150 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Envisagenics raised?
Envisagenics has raised $40.5 million in total; 2 of its rounds are on record. The largest on record was a $2.5 million seed round in Mar 2017; the most recent was a $19.2 million early-stage round in Sep 2021.
Envisagenics has filed 3 Form Ds with the SEC since 2017, most recently in Oct 2021 ($19.2 million sold to 24 investors).
Envisagenics investors
24 investors are on record for Envisagenics, including SV Angel, National Institutes of Health, M12 and Madrona Venture Group. By type, the record holds 6 venture capital firms and 1 family office. The early-stage round in Sep 2021 drew 24 investors.
About Envisagenics
Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine learning algorithms to analyze, predict, and interpret transcriptomic data, enabling researchers to identify and validate potential drug targets.
- Sector
- Healthcare
- HQ
- Long Island City, NY, United States
- Founded
- 2014
- Employees
- 49
- Website
- envisagenics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Envisagenics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.